DE60002984D1 - Neue verwendung von orexinrezeptorantagonisten - Google Patents

Neue verwendung von orexinrezeptorantagonisten

Info

Publication number
DE60002984D1
DE60002984D1 DE60002984T DE60002984T DE60002984D1 DE 60002984 D1 DE60002984 D1 DE 60002984D1 DE 60002984 T DE60002984 T DE 60002984T DE 60002984 T DE60002984 T DE 60002984T DE 60002984 D1 DE60002984 D1 DE 60002984D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
orexine
new use
neuroprotectants
nausea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60002984T
Other languages
English (en)
Other versions
DE60002984T2 (de
Inventor
Elaine Alison Irving
Gareth John Sanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903265.8A external-priority patent/GB9903265D0/en
Priority claimed from GBGB9903284.9A external-priority patent/GB9903284D0/en
Priority claimed from GBGB9903282.3A external-priority patent/GB9903282D0/en
Priority claimed from GBGB9903278.1A external-priority patent/GB9903278D0/en
Priority claimed from GBGB9906061.8A external-priority patent/GB9906061D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60002984D1 publication Critical patent/DE60002984D1/de
Publication of DE60002984T2 publication Critical patent/DE60002984T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60002984T 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten Expired - Fee Related DE60002984T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9903265.8A GB9903265D0 (en) 1999-02-12 1999-02-12 Novel use
GB9903265 1999-02-12
GBGB9903284.9A GB9903284D0 (en) 1999-02-12 1999-02-12 Novel use
GB9903284 1999-02-12
GBGB9903282.3A GB9903282D0 (en) 1999-02-12 1999-02-12 Novel use
GB9903278 1999-02-12
GBGB9903278.1A GB9903278D0 (en) 1999-02-12 1999-02-12 Novel compounds
GB9903282 1999-02-12
GBGB9906061.8A GB9906061D0 (en) 1999-03-17 1999-03-17 Novel use
GB9906061 1999-03-17
PCT/EP2000/001147 WO2000047284A2 (en) 1999-02-12 2000-02-10 Novel use of orexin receptor antagonists

Publications (2)

Publication Number Publication Date
DE60002984D1 true DE60002984D1 (de) 2003-07-03
DE60002984T2 DE60002984T2 (de) 2004-03-11

Family

ID=27517496

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60002984T Expired - Fee Related DE60002984T2 (de) 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten

Country Status (8)

Country Link
US (1) US6506774B1 (de)
EP (2) EP1352651A3 (de)
JP (1) JP2002536425A (de)
AT (1) ATE241345T1 (de)
AU (1) AU2548400A (de)
DE (1) DE60002984T2 (de)
ES (1) ES2199770T3 (de)
WO (1) WO2000047284A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536425A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー オレキシン受容体アンタゴニストの新規用途
WO2002087606A2 (en) * 2000-12-20 2002-11-07 Sri International Modulators of the hypocretin system and methods of screening therefor
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
CA2557163C (en) 2004-03-01 2011-08-16 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2015048091A1 (en) * 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US20190083508A1 (en) * 2014-11-24 2019-03-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
CA3071972A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034877A1 (en) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) * 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) * 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) * 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999030670A2 (en) * 1997-12-15 1999-06-24 Smithkline Beecham Plc Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
EP1075478B1 (de) 1998-05-08 2003-04-16 SmithKline Beecham plc Phenylurea und phenylthio urea derivate
ATE314371T1 (de) * 1998-11-10 2006-01-15 Merck & Co Inc Spiro-indole als y5-rezeptor antagonisten
JP2002536425A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー オレキシン受容体アンタゴニストの新規用途
WO2000047580A2 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives

Also Published As

Publication number Publication date
DE60002984T2 (de) 2004-03-11
WO2000047284A2 (en) 2000-08-17
EP1352651A3 (de) 2003-11-12
WO2000047284A3 (en) 2000-12-14
EP1352651A2 (de) 2003-10-15
ATE241345T1 (de) 2003-06-15
AU2548400A (en) 2000-08-29
ES2199770T3 (es) 2004-03-01
EP1150664A2 (de) 2001-11-07
EP1150664B1 (de) 2003-05-28
US6506774B1 (en) 2003-01-14
JP2002536425A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ATE360032T1 (de) Cystein-reiche rezeptoren-train
ATE242243T1 (de) Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
DE69943352D1 (de) Azabicycloalkane als ccr5-modulatoren
BR9707391A (pt) Pirazolpirimidinas como antagonistas de receptor de crf
DE69627716D1 (de) Perfluorelastomer-zusammensetzung mit erhöhter vulkanisationseigenschaften
AP2000001949A0 (en) 4-Benzyl piperidine alkysulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists.
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
SE9702773D0 (sv) Novel compounds
BR9704117B1 (pt) derivados de insulina com maior ligação com zinco.
ITTO991021A0 (it) Antagonisti ii del recettore ccr-3.
DE69204040D1 (de) 3-Phenylureido-1,4-Benzodiazepinone und ihre Verwendung als Cholecystokinin- oder Gastrinantagonisten.
PT885215E (pt) Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
IT1318319B1 (it) Composizione di gomma, procedimento per produrre la stessa e manicottoutilizzante la composizione di gomma.
ATE194595T1 (de) Benzonitrile als 5-ht agonisten und antagonisten
DK1021541T3 (da) Aminoterminalt trunkeret MCP-2 som chemokinantagonister
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
DE60002984D1 (de) Neue verwendung von orexinrezeptorantagonisten
DE60024652D1 (de) Unkonjugiertes cyklisches polyencopolymer, kautschukzusammensetzung und verwendung
DE69740099D1 (de) Transdermale zusammenstellung mit serotoninrezeptor-antagonist
PT923550E (pt) Derivados de acilaminoalcenileno-amida como antagonistas de nk1 e nk2
PT964863E (pt) Oxazolidinonas como antagonistas de 5-ht2a
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee